



HARVARD MEDICAL SCHOOL

Earn up to 49.75 AMA PRA Category 1 Credits™

CANCER MEDICINE and HEMATOLOGY

September 27 – October 2, 2015

Boston, MA

Updates, best practices, new guidelines and innovations to optimize planning and care for patients with cancer and hematologic disorders



Updates and education covering:

- Familial syndromes
- Personalized oncologic management
- Targeted therapies
- Symptom control
- Treating hypercoagulable conditions
- Using novel anticoagulants
- Immune therapy
- Management of cancer survivors
- Palliative care
- Advances in cancer drugs
- ABIM Maintenance of Certification (MOC)

(Full program inside)

Under the direction of Robert J. Mayer, MD

DANA-FARBER/PARTNERS CANCERCARE



Register at CancerMedicine.HMSCME.com



HARVARD

MEDICAL SCHOOL

Dear Colleague:

In the past year, we have seen considerable advances in cancer medicine and hematology. These changes have significant implications for our approach to malignant conditions, benign hematologic disorders, familial cancer syndromes, palliative care, symptom control, and management of cancer survivors. The best patient care and outcomes require us to stay current with these changes and incorporate them into practice. This is the mission of this annual program—to quickly and effectively apprise you of these updates, their clinical implications, and how best to integrate important advances into practice.

I encourage you to join us in Boston for this program. Year after year, attendees report that the week spent out of their offices and dedicated to updating and advancing their skills proves invaluable to them and their patients.

You will find that this program is unique in two ways. The first is that education is provided by Harvard Medical School's leading clinical faculty and by the country's foremost authorities in cancer medicine and hematology. The second is the interactive and collegial nature of the program. These experts welcome questions and robust interaction with attendees. We actively encourage you to bring your questions and get them answered, and to be our guest at a special networking dinner at the Harvard Club, featuring insights from Dr. Ezekiel J. Emanuel, whom many of you may recognize from his work and as a frequent contributor to the op-ed pages of the *New York Times*. He will be speaking to us about megatrends and the future of American health care and its implications for us as practitioners.

My colleagues and I look forward to welcoming you to Boston in September.

Sincerely yours,



Robert J. Mayer, MD

Course Chair

Faculty Vice President for Academic Affairs

Dana-Farber Cancer Institute

Stephen B. Kay Family Professor of Medicine

Harvard Medical School

Who Should Attend

- Oncologists
- Hematologists
- Internists
- Fellows
- Physician Assistants
- Advanced Practice Nurses

...and other clinicians who care for and treat patients with hematologic (benign and malignant) and oncologic conditions

Course Description

This intensive six-day activity is designed to provide a comprehensive review for practitioners of the clinical, molecular, and pathophysiologic basis for the diagnosis and treatment of neoplastic diseases and benign hematologic disorders. Primary emphasis will be placed upon the broad area of medical management. Recent advances in molecular genetics, clinical pharmacology, epidemiology, and supportive care will be stressed. Teaching will be primarily through lectures, panels and case discussions with the assistance of appropriate visual aids.

Learning Objectives

After participating in this program, learners will be able to:

- Evaluate, treat and manage patients with hematologic disorders more effectively by making appropriate use of current and emerging therapies, cytological characteristics, and molecular diagnostics tests
- Improve care for breast cancer patients by incorporating novel targeted therapies and molecular diagnostics testing into current treatment paradigms
- Create multimodal treatment plans for lung, head and neck cancers that utilize newly approved therapies and conform more closely to current expert recommendations
- Improve treatment of patients with gastrointestinal and neuroendocrine cancers with more effective uses of molecular diagnostics and available systemic therapies
- Provide care for prostate, testicular, renal and bladder cancers that is tailored to individual patients and their risk factors and makes appropriate use of new and emerging therapies
- Utilize genetic testing, novel treatment approaches, and palliative care to create optimized care plans for patients with ovarian, cervical, endometrial, and trophoblastic cancers
- Incorporate new therapies where available and new clinical trial data into management plans for a wide range of less common cancers, including brain tumors, thyroid cancer, melanoma, sarcoma, and mesothelioma
- Provide effective supportive and palliative care by actively managing pain, depression, dementia, emesis, insomnia, infection, and other aspects of cancer and cancer treatment that can detract from patient quality of life and produce less than optimal outcomes

Disclosure Policy

Harvard Medical School (HMS) adheres to all ACCME Essential Areas, Standards, and Policies. It is HMS's policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.

Agenda

Saturday, September 26, 2015

5:30 pm - 8:30 pm **Registration**

Sunday, September 27, 2015

7:00 am - 8:45 am **Registration & Breakfast**

8:45 am - 9:00 am

Welcome

Robert J. Mayer, MD

9:00 am - 10:00 am

Stem Cell Biology and Hematopoietic Growth Factors

David J. Kuter, MD, DPhil

10:00 am - 11:00 am

Leukocyte Disorders

Nancy Berliner, MD

11:00 am - 11:15 am **Break**

11:15 am - 12:15 pm

Hemolytic Anemias

Jean M. Connors, MD

12:15 pm - 1:15 pm

Bone Marrow Failure States

Robert A. Brodsky, MD

1:15 pm - 2:15 pm **Lunch break**

2:15 pm - 3:15 pm

Thrombocytopenias

Kenneth Kaushansky, MD

3:15 pm - 4:00 pm

Iron Deficiency and Iron Overload

Mark D. Fleming, MD, DPhil

4:00 pm - 4:15 pm **Break**

4:15 pm - 5:15 pm

Hemoglobinopathies

Matthew M. Heeney, MD

5:15 pm - 6:15 pm

Transfusion Medicine for the Clinician

Walter H. Dzik, MD

Program changes/substitutions may be made without notice.

Agenda

Monday, September 28, 2015

7:00 am - 8:00 am **Breakfast**

8:00 am - 9:00 am

Platelet Function and von Willebrand's Disease

Robert I. Handin, MD

9:00 am - 10:15 am

Hypercoagulable Syndromes and New Anticoagulant Therapies

Kenneth A. Bauer, MD

10:15 am - 10:30 am Break

10:30 am - 11:30 am

Hemophilia-Related Syndromes

Ellis J. Neufeld, MD, PhD

11:30 am - 12:00 pm

Panel Discussion

Drs. Bauer, Handin, and Neufeld

12:00 pm - 1:00 pm Lunch break

1:00 pm - 2:00 pm

Molecular Genetics of Cancer

Eliezer M. Van Allen, MD

2:00 pm - 3:00 pm

Advances in Cancer Drug Development

Keith T. Flaherty, MD

3:00 pm - 3:15 pm Break

3:15 pm - 4:00 pm

Infections in the Immunocompromised Host

Nicholas C. Issa, MD

4:00 pm - 5:00 pm

Plasma Cell Neoplasms

Kenneth C. Anderson, MD

Tuesday, September 29, 2015

7:00 am - 8:00 am **Breakfast**

8:00 am - 9:00 am

Biology of Bone Marrow Transplantation

Robert J. Soiffer, MD

9:00 am - 9:45 am

Myelodysplasia

Timothy A. Graubert, MD

9:45 am - 10:45 am

Acute Myeloid Leukemia Richard M. Stone, MD

10:45 am - 11:00 am Break

11:00 am - 11:45 am

Chronic Myeloid Leukemia

Daniel J. DeAngelo, MD, PhD

11:45 am - 12:30 pm

Myeloproliferative Syndromes

Ayalew Tefferi, MD

12:30 pm - 1:00 pm

Panel Discussion

Drs. DeAngelo, Graubert, Stone, and Tefferi

1:00 pm - 2:00 pm Lunch break

2:00 pm - 2:40 pm

Low Grade Lymphoma

Jeremy S. Abramson, MD

2:40 pm - 3:30 pm

High Grade Lymphoma Arnold S. Freedman, MD

3:30 pm - 3:45 pm Break

3:45 pm - 4:30 pm

Hodgkin Lymphoma George P. Canellos, MD

4:30 pm - 5:15 pm

CLL and Variants John C. Byrd, MD

5:15 pm - 5:45 pm

Panel Discussion

Drs. Abramson, Byrd, Canellos, and Freedman

5:45 pm - 7:00 pm Break

7:00 pm - 9:30 pm

ABIM Maintenance of Certification (MOC) Session: 2015 Update in Medical Oncology Module

Harold J. Burstein, MD, PhD; Daniel J. DeAngelo, MD, PhD; and Robert J. Mayer, MD

Light dinner provided



This course provides comprehensive updates on new and emerging therapies

Agenda

Wednesday, September 30, 2015

7:00 am - 8:00 am **Breakfast**

8:00 am - 8:30 am

Neuroendocrine Tumors

Matthew H. Kulke, MD

8:30 am - 9:00 am

Gastrointestinal Malignancies: Genetics and Screening

Sapna Syngal, MD, MPH

9:00 am - 9:45 am

Gastrointestinal Malignancies: Esophageal and Gastric

Charles S. Fuchs, MD, MPH

9:45 am - 10:00 am Break

10:00 am - 10:45 am

Gastrointestinal Malignancies: Pancreas and Hepatobiliary

David P. Ryan, MD

10:45 am - 11:45 am

Gastrointestinal Malignancies: Colorectal and Anal

Robert J. Mayer, MD

11:45 am - 12:15 pm

Panel Discussion

Drs. Fuchs, Kulke, Mayer, Ryan, and Syngal

12:15 pm - 1:15 pm Lunch break

1:15 pm - 2:15 pm

Sarcoma and GIST George D. Demetri, MD

2:15 pm - 3:00 pm

Thymic Tumors Patrick J. Loehrer, MD

3:00 pm - 3:40 pm

Clinical Essentials of Palliative Care

Janet L. Abraham, MD

3:40 pm - 3:55 pm Break

3:55 pm - 4:55 pm

Gynecologic Cancer: Ovarian

Stephen A. Cannistra, MD

4:55 pm - 5:45 pm

Gynecologic Cancer: Cervical, Endometrial, Trophoblastic

Ursula A. Matulonis, MD

5:45 pm - 6:15 pm

Panel Discussion

Drs. Cannistra and Matulonis

Thursday, October 1, 2015

7:00 am - 8:00 am **Breakfast**

8:00 am - 9:00 am

Thyroid Cancer Gilbert H. Daniels, MD

9:00 am - 10:00 am

Melanoma F. Stephen Hodi, MD

10:00 am - 10:15 am Break

10:15 am - 11:05 am

Head and Neck Cancer Robert I. Haddad, MD

11:05 am - 11:45 am

Lung Cancer: Non-Small Cell I Thomas J. Lynch, MD

11:45 pm - 12:25 pm

Lung Cancer: Non-Small Cell II, Small Cell, Mesothelioma Bruce E. Johnson, MD

12:25 pm - 12:45 pm

Emerging Targeted Therapies for Lung Cancer; Brain Metastases Alice T. Shaw, MD, PhD

12:45 am - 1:00 pm

Panel Discussion

Drs. Haddad, Johnson, Lynch, and Shaw

1:00 pm - 2:00 pm Lunch break

2:00 pm - 3:00 pm

Neuro-Oncology Tracy T. Batchelor, MD, MPH

3:00 pm - 3:45 pm

Genitourinary Cancer: Testicular William K. Oh, MD

3:45 pm - 4:00 pm Break

4:00 pm - 4:45 pm

Genitourinary Cancer: Renal and Bladder M. Dror Michaelson, MD, PhD

4:45 pm - 5:45 pm

Genitourinary Cancer: Prostate Philip W. Kantoff, MD

5:45 pm - 6:15 pm

Panel Discussion

Drs. Kantoff, Michaelson, and Oh

6:15 pm - 7:00 pm Break

7:00 pm - 10:00 pm

Dinner/Lecture at the Harvard Club:
“Megatrends: The Future of American Health Care”

Ezekiel J. Emanuel, MD, PhD

Agenda

Friday, October 2, 2015

7:00 am - 8:00 am **Breakfast**

8:00 am - 8:05 am

Welcome and Introduction

Lawrence N. Shulman, MD

8:05 am - 9:00 am

Survivorship Issues in Breast Cancer and Other Malignancies

Ann H. Partridge, MD, MPH

9:00 am - 9:35 am

Breast Cancer Epidemiology, Risk, Genetics and Prevention

Judy E. Garber, MD, MPH

9:35 am - 10:15 am

Breast Cancer: Pre-Invasive Disease, Surgery, Radiation, Hormonal Therapy

Harold J. Burstein, MD, PhD

10:15 am - 10:30 am Break

10:30 am - 11:10 am

Breast Cancer: Adjuvant and Neoadjuvant Therapy

Eric P. Winer, MD

11:10 am - 11:50 am

Breast Cancer: Metastatic Disease

Ian E. Krop, MD, PhD

11:50 am - 12:15 pm

Panel Discussion

Drs. Burstein, Garber, Krop, Partridge, and Winer

12:15 pm - 12:30 pm

Concluding Remarks

Robert J. Mayer, MD

Venue

The Fairmont Copley Plaza
138 St. James Avenue | Boston, Massachusetts
+1 617-267-5300



Registration Information

Cancer Medicine and Hematology

September 27 – October 2, 2015
Boston, MA • Course #732059-1601

Register after May 31, 2015	Register on or before May 31, 2015
\$1500	\$1300 (Save \$200)

Tuition includes all breakfasts and afternoon snacks, the 2015 ABIM MOC session with light dinner on Tuesday evening, and a special dinner and lecture at the Harvard Club on Thursday evening.

Registration, Payment, Confirmation and Refund Policy

Registrations for Harvard Medical School CME programs are made via our secure online registration system. To register for this course, please visit the course website.

At the end of the registration process you will have the choice of paying by check or credit card (VISA, MasterCard or American Express). If you are paying by check, the online registration system will provide you with instructions and a printable form for remitting your course fees by check. Postal, telephone, fax, and cash-payment registrations are not accepted.

Upon receipt of your paid registration, an email confirmation from the HMS DCE office will be sent to you. **Be sure to include an email address that you check frequently.** Your email address is used for critical information, including registration confirmation, evaluation, and certificate. Refunds, less an administrative fee of \$75, will be issued for all cancellations received two weeks prior to the start of the course. Refund requests must be received by postal mail, email, or fax. No refund will be issued should cancellation occur less than two weeks prior. "No shows" are subject to the full course fee and no refunds will be issued once the conference has started.

Accommodations

A limited number of rooms have been reserved at the Fairmont Copley Plaza Hotel (Telephone: 617-267-5300) **until September 5, 2015.** Please specify that you are enrolled in this course to receive a reduced room rate. Hotel arrangements can also be made online by visiting our website at CancerMedicine.HMSCME.com.

Please do not make non-refundable travel arrangements until you have received an email from the HMS-DCE office confirming your paid registration.

Register at CancerMedicine.HMSCME.com

Harvard Medical School Faculty

Janet L. Abrahm, MD
Jeremy S. Abramson, MD
Kenneth C. Anderson, MD
Tracy T. Batchelor, MD, MPH
Kenneth A. Bauer, MD
Edward J. Benz, Jr., MD
Nancy Berliner, MD
Harold J. Burstein, MD, PhD
George P. Canellos, MD
Stephen A. Cannistra, MD
Jean M. Connors, MD
Gilbert H. Daniels, MD
Daniel J. DeAngelo, MD, PhD
George D. Demetri, MD
Walter H. Dzik, MD

Keith T. Flaherty, MD
Mark D. Fleming, MD, DPhil
Arnold S. Freedman, MD
Charles S. Fuchs, MD, MPH
Judy E. Garber, MD, MPH
Timothy A. Graubert, MD
Robert I. Haddad, MD
Robert I. Handin, MD
Matthew M. Heeney, MD
F. Stephen Hodi, MD
Nicholas C. Issa, MD
Bruce E. Johnson, MD
Philip W. Kantoff, MD
Ian E. Krop, MD, PhD
Matthew H. Kulke, MD

David J. Kuter, MD, DPhil
Ursula A. Matulonis, MD
Robert J. Mayer, MD
M. Dror Michaelson, MD, PhD
Ellis J. Neufeld, MD, PhD
Ann H. Partridge, MD, MPH
David P. Ryan, MD
Alice T. Shaw, MD, PhD
Robert J. Soiffer, MD
Richard M. Stone, MD
Sapna Syngal, MD, MPH
Eliezer M. Van Allen, MD
Eric P. Winer, MD

Guest Faculty

Robert A. Brodsky, MD

Professor of Medicine, Johns Hopkins School of Medicine
Chief of Hematology, Sidney Kimmel Comprehensive Cancer Center

John C. Byrd, MD

Professor of Medicine and Medicinal Chemistry;
D. Warren Brown Chair of Leukemia Research;
Director, Division of Hematology, Department of Internal Medicine, Ohio State University

Ezekiel J. Emanuel, MD, PhD

Vice Provost for Global Initiatives; Diane v.S. Levy and Robert M. Levy University Professor;
Chair, Department of Medical Ethics and Health Policy, University of Pennsylvania

Kenneth Kaushansky, MD

Senior Vice President of the Health Sciences;
Dean of the School of Medicine, Stony Brook University

Patrick J. Loehrer, Sr., MD

Director, Indiana University Melvin and Bren Simon Cancer Center
H.H. Gregg Professor of Oncology and Associate Dean for Cancer Research, Indiana University School of Medicine

Thomas J. Lynch, Jr., MD

Richard Sackler and Jonathan Sackler Professor of Medicine (Medical Oncology), Yale University School of Medicine
Director, Yale Comprehensive Cancer Center

William K. Oh, MD

Professor of Medicine and Urology,
Icahn School of Medicine at Mount Sinai
Chief, Division of Hematology-Oncology,
Mount Sinai Comprehensive Cancer Center

Lawrence N. Shulman, MD

Deputy Director for Clinical Service,
Abramson Cancer Center,
University of Pennsylvania

Ayalew Tefferi, MD

Professor of Medicine, Mayo Clinic College of Medicine

Accreditation

The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Harvard Medical School designates this live activity for a maximum of *49.75 AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria of the Massachusetts Board of Registration in Medicine for .75 credits of Risk Management Study. This includes .75 credits of End-of-Life Care Studies. Please check your individual state licensing board requirements before claiming these credits.

The Royal College of Physicians and Surgeons of Canada recognizes conferences and workshops held outside of Canada that are developed by a university, academy, hospital, specialty society or college as accredited group learning activities.

AMA PRA Category 1 Credits™ claimed by physicians attending live events certified and organized in the United States for *AMA PRA Category 1 Credits™* can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the **European Continuous Medical Education Credits (ECMEC®)** granted by the UEMS. One *AMA PRA Category 1 Credit™* is equivalent to one (1) hour of European EACCME Credit (ECMEC®), therefore up to 49.75 ECMEC® Credits are available. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

ACGME Competencies

This course is designed to meet the following Accreditation Council of Graduate Medical Education competencies: patient care, medical knowledge, practice-based learning and improvement, and interpersonal and communication skills.